Atsena Therapeutics, a Durham, NC-based clinical-stage gene remedy firm, raised $150M in Collection C funding.
The spherical was led by Bain Capital’s Life Sciences workforce, with participation from a further new investor, Wellington Administration, and present traders together with Lightstone Ventures, Sofinnova Investments, Abingworth, Basis Combating Blindness, Hatteras Enterprise Companions, Osage College Companions, and the Manning Household Basis.
The corporate intends to make use of the funds to advance its lead program, ATSN-201, for the therapy of X-linked retinoschisis (XLRS), a genetic situation that’s sometimes identified in childhood and results in blindness later in life.
Led by CEO Patrick Ritschel, Atsena Therapeutics is a clinical-stage gene remedy firm growing therapies for the reversal or prevention of blindness from inherited retinal illnesses. Its lead program is evaluating ATSN-201 in an ongoing Part I/II medical trial for X-linked retinoschisis (XLRS), a genetic situation that’s sometimes identified in childhood and results in blindness later in life. ATSN-101, Atsena’s investigational gene remedy for Leber congenital amaurosis sort 1 (LCA1), has accomplished a Part 1/2 trial with optimistic outcomes. It’s advancing ATSN-101 towards the initiation of a worldwide pivotal trial as a part of its unique strategic collaboration with Nippon Shinyaku Co., Ltd.
Along side the financing, Norbert Riedel, PhD, a scientist and biopharmaceutical government, will be a part of Atsena’s Board of Administrators.
FInSMEs
04/04/2025
